Wave Life Sciences Ltd. is a pharmaceutical company based in Singapore specializing in RNA medicines. With an ESG risk rating score of 33.5, the company is considered to have high risk. Wave Life Sciences is dedicated to transforming human health by targeting ribonucleic acid (RNA) through its PRISM platform, which combines various modalities and chemistry innovations. These RNA-targeting modalities include editing, splicing, silencing, and interference to effectively address disease biology. Wave Life Sciences focuses on developing treatments for rare and prevalent disorders such as alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.